20 September 2023: Clinical Research
Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II–III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy
Radu Valeriu Toma 12ABCG , Zgura Anca 1E , Oana Gabriela Trifănescu 12A , Laurenţia Nicoleta Galeş 12D* , Antonia Ruxandra Folea 2CDEF , Loredana Stanca 3B , Liviu Bîlteanu 234ABCDEF* , Rodica M. Anghel 1ADOI: 10.12659/MSM.941754
Med Sci Monit 2023; 29:e941754
Supplementary Table 11 RR and OR calculation for the associations presented in Figure 2 of the manuscript between an echocardiographic outcome variable and the dosimetric predictor variables.
| Notations | Explanation | Example |
|---|---|---|
| Predictor or independent variable | dosimetric variables (i.e. maximum dose, mean dose and V25 for LAD and the maximum dose and V25 for the whole heart or LAD) | |
| Classical percentiles α=0.25, 0.33, 0.50, 0.67 and 0.75 of the predictor variable | The values of dosimetric variables’ percentiles can be found in .Table S8 | |
| → {0,1} | Outcome variable with two realizations | decrease in EF by 5% during treatment administration |
| = 0 | A EF drop of at least 5% does not occur | |
| = 1 | A EF drop of at least 5% occurs | |
| (.) | Probability of an event | P( = 0) probability that no EF drop of at least 5% occurred within our study group |
| (.|.) | Conditional probability | probability that no EF drop of at least 5% occurred within our study group knowing that the condition is valid, i.e. the value of the dosimetric variable is greater or equal than its 0.75 percentile that can be found inSupplementary Table 8 |
| The relative risk and the odds ratio corresponding to the association between the decrease of EF by at least 5% during the multimodal treatment (Y = 1) and a maximum LAD dose higher than the 0.75 percentile calculated in the study group (i.e. 46.9 Gy, see ) are written as follows:andSupplementary Table 8 | ||